{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:54:46Z","timestamp":1788195286088,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019331","name":"Henan Medical Science and Technique Foundation","doi-asserted-by":"crossref","award":["grant number 2018020484"],"award-info":[{"award-number":["grant number 2018020484"]}],"id":[{"id":"10.13039\/501100019331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,7,2]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV infection undergoing anticancer therapy. There is a risk of HBV reactivation after infusion of chimeric antigen receptor (CAR) T cells for patients with refractory\/relapsed (R\/R) multiple myeloma (MM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We administered B cell maturation antigen (BCMA) CAR-T cell by infusion to nine patients with R\/R MM with chronic or resolved HBV infection. Patient serum was analyzed to determine the expression of five components of HBV and the copy number of HBV DNA. HBV reactivation was defined if a patient re-exhibited hepatitis B surface antigen (HBsAg) or HBV DNA regrowth after CAR-T therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In one patient who was HBsAg-positive, no HBV reactivation was observed during the follow-up period of 9.8 months after administration of anti-HBV drugs before and after CAR-T therapy. Among eight patients with MM who had resolved HBV infection, two patients administered prophylactic anti-HBV drugs did not exhibit HBV reactivation. Of the six patients who did not use prophylactic antiviral drugs, five did not exhibit HBV reactivation, while one showed recurrence of HBsAg without detection of HBV DNA or damage to liver function. The best objective response rate was 100%, and the progression-free survival (PFS) at 12 months was of 88.89% (median PFS was not observed).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings showed that BCMA CAR-T cell therapy could be used in patients with R\/R MM with chronic or resolved HBV infection and that antiviral drugs should be administered in these patients during CAR-T cell therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000927","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T10:41:42Z","timestamp":1597401702000},"page":"e000927","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03664661","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lu","family":"Han","sequence":"first","affiliation":[{"name":"Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishuai","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Shenzhen Pregene Biopharma Company, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-0276","authenticated-orcid":false,"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2025100305100495000_8.2.e000927.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"2025100305100495000_8.2.e000927.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22945"},{"key":"2025100305100495000_8.2.e000927.3","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0"},{"key":"2025100305100495000_8.2.e000927.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440120"},{"key":"2025100305100495000_8.2.e000927.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.015"},{"key":"2025100305100495000_8.2.e000927.6","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50220"},{"key":"2025100305100495000_8.2.e000927.7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1750-z"},{"key":"2025100305100495000_8.2.e000927.8","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50171"},{"key":"2025100305100495000_8.2.e000927.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1104"},{"key":"2025100305100495000_8.2.e000927.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703826"},{"key":"2025100305100495000_8.2.e000927.11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i40.14581"},{"key":"2025100305100495000_8.2.e000927.12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/eri.11.79","article-title":"Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation","volume":"9","author":"Idilman","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025100305100495000_8.2.e000927.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0182"},{"key":"2025100305100495000_8.2.e000927.14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/cas.13239","article-title":"Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"108","author":"Makita","year":"2017","journal-title":"Cancer Sci"},{"key":"2025100305100495000_8.2.e000927.15","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc1800913","article-title":"Car T-cell therapy in large B-cell lymphoma","volume":"378","author":"Neelapu","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100305100495000_8.2.e000927.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869"},{"key":"2025100305100495000_8.2.e000927.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"2025100305100495000_8.2.e000927.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2025100305100495000_8.2.e000927.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"2025100305100495000_8.2.e000927.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2025100305100495000_8.2.e000927.21","first-page":"266","article-title":"Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and\/or bortezomib","volume":"36","author":"Ataca Atilla","year":"2019","journal-title":"Turk J Haematol"},{"key":"2025100305100495000_8.2.e000927.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100305100495000_8.2.e000927.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2025100305100495000_8.2.e000927.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"2025100305100495000_8.2.e000927.25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2025100305100495000_8.2.e000927.26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"2025100305100495000_8.2.e000927.27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"2025100305100495000_8.2.e000927.28","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"2025100305100495000_8.2.e000927.29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"2025100305100495000_8.2.e000927.30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"2025100305100495000_8.2.e000927.31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10428194.2011.610013","article-title":"High prevalence of hepatitis B virus infection in multiple myeloma","volume":"53","author":"Huang","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2025100305100495000_8.2.e000927.32","first-page":"1718","article-title":"[Monitoring of HBsAg and Risk of HBV Infection in Patients with Multiple Myeloma]","volume":"25","author":"He","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2025100305100495000_8.2.e000927.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-005-0385-z"},{"key":"2025100305100495000_8.2.e000927.34","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500062932"},{"key":"2025100305100495000_8.2.e000927.35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403914"},{"key":"2025100305100495000_8.2.e000927.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000888"},{"key":"2025100305100495000_8.2.e000927.37","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0790-y"},{"key":"2025100305100495000_8.2.e000927.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0748-4"},{"key":"2025100305100495000_8.2.e000927.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1403"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:10:16Z","timestamp":1759493416000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jitc-2020-000927"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000927","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}